4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes-Reference-Cited by-同舟云学术

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes

Published:2015-08-12 Issue:3 Volume:80 Page:560-568
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

de Graan Anne-Joy M.¹,Sparreboom Alex¹²,de Bruijn Peter¹,de Jonge Evert³,van der Holt Bronno⁴,Wiemer Erik A. C.¹,Verweij Jaap¹,Mathijssen Ron H. J.¹,van Schaik Ron H. N.³

Affiliation:

1. Department of Medical Oncology; Erasmus MC Cancer Institute; 's-Gravendijkwal 230 3015CE Rotterdam

2. Department of Pharmaceutical Sciences; St Jude Children's Research Hospital; 262 Danny Thomas Place 38105-3678 Memphis TN USA

3. Department of Clinical Chemistry; Erasmus University Medical Center; 's-Gravendijkwal 230 3015CE Rotterdam the Netherlands

4. Department of Trials and Statistics; Erasmus University Medical Center; 's-Gravendijkwal 230 3015CE Rotterdam the Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12707/fullpdf

Reference42 articles.

1. Combining taxanes with radiation for solid tumors;Choy;Int J Cancer,2000

2. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients;Henningsson;Eur J Cancer,2003

3. Managing taxane toxicities;Markman;Support Care Cancer,2003

4. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer;Bruno;J Clin Oncol,1998

5. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel;Bruno;Invest New Drugs,2001

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment;Therapeutic Advances in Medical Oncology;2022-01

2. Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem;Scientific Reports;2021-09-27

3. CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women;Cancers;2021-09-18

4. Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects;Drug Metabolism and Pharmacokinetics;2021-02

5. The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects;Drug Metabolism and Pharmacokinetics;2021-02